Could a simple infusion let celiac patients eat gluten again?
NCT ID NCT05660109
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called TPM502 in 28 adults with celiac disease. The goal was to see if two infusions of TPM502 could safely train the immune system to tolerate gluten, potentially reducing the need for a lifelong gluten-free diet. Participants received either TPM502 or a placebo and underwent gluten challenges to measure immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TPM502 (a mixture of gluten protein fragments designed to train the immune system to tolerate gluten)
What this could lead to
If it works, this could point toward a treatment that allows people with celiac disease to eat gluten without harm, reducing the need for a strict gluten-free diet.
What could go wrong
This is a small, early-phase trial (28 people) focused on safety and immune markers, not on actual symptom relief. The treatment may not produce meaningful tolerance, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRST Oy
Turku, FI-20520, Finland
-
Centre for Human Drug Research
Leiden, 2333 ZA, Netherlands
-
Charite' Hospital
Berlin, 12200, Germany
-
Clinical Trial Consultants, Uppsala University
Uppsala, 752 37, Sweden
-
Oslo University Hospital HF - Rikshospitalet
Oslo, 0372, Norway
-
Royal Adelaide Hospital
Adelaide, 5000, Australia
-
University Hospital of North-Norway
Tromsø, 9038, Norway
-
Wesley Research Institute
Brisbane, 4066, Australia